Nice presentation. Looks like MD has finally realised that marketing as impt as proving the drug.
Key takes:
Partnering and Corporate engagement:
I am confident someone is in deep discussions.
P2b timeline / funding:
The last line again talks about corporate engagement for finding.
ATL1103 :
We would though expect our shareholders to regard the potential monetisation of ATL1103 as more of an upside opportunity, while we look to lock in the solid value creation potential of ATL1102.
Good luck holders. MD looking to increase the MC / SP is positive. Having Wilsons report at the start of preso is a fantastic start...
All IMO..
Ann: 2020 Annual General Meeting Presentation, page-2
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.0¢ |
Change
0.003(3.90%) |
Mkt cap ! $72.12M | |||
| Open | High | Low | Value | Volume |
| 7.9¢ | 8.3¢ | 7.9¢ | $147.1K | 1.826M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300000 | 7.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.3¢ | 106165 | 2 |
View Market Depth
| Last trade - 16.10pm 08/05/2024 (20 minute delay) ? |
|
|||||
|
Last
8.0¢ |
Change
0.003 ( 3.90 %) |
||||
| Open | High | Low | Volume | ||
| 7.9¢ | 8.3¢ | 7.9¢ | 108394 | ||
| Last updated 15.59pm 08/05/2024 ? | |||||
| PER (ASX) Chart |